Febuxostat (Adenuric) for the treatment of chronic hyperuricaemia
In conclusion, febuxostat can be said to have an equal value in comparison to allopurinol in the treatment of adult patients with hyperuricaemia, urate deposition and gouty symptoms. Febuxostat has an added therapeutic value in comparison to benzbromarone for the treatment of chronic hyperuricaemia in patients who cannot (or can no longer) be treated with allopurinol or do not respond to this treatment.